Inhibikase Therapeutics, Inc.

Equities

IKT

US45719W2052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
1.34 ^USD	-0.74%		-29.47%	+5.51%

Apr. 03	Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension	CI
Mar. 28	Transcript : Inhibikase Therapeutics, Inc., 2023 Earnings Call, Mar 28, 2024

Inhibikase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 14, 2023 at 04:08 pm EDT

Inhibikase Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 0.11641 million compared to USD 0.006552 million a year ago. Net loss was USD 5.78 million compared to USD 4.64 million a year ago. Basic loss per share from continuing operations was USD 1.11 compared to USD 1.1 a year ago.
For the six months, revenue was USD 0.180931 million compared to USD 0.052583 million a year ago. Net loss was USD 10.26 million compared to USD 9.28 million a year ago. Basic loss per share from continuing operations was USD 2.09 compared to USD 2.2 a year ago.

Latest news about Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension	Apr. 03	CI
Transcript : Inhibikase Therapeutics, Inc., 2023 Earnings Call, Mar 28, 2024	Mar. 28
Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts 2023 Revenue $260,501	Mar. 27	MT
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders	Mar. 07	CI
Maxim Initiates Inhibikase Therapeutics With Buy Rating, Price Target is $8	Feb. 20	MT
Inhibikase Therapeutics Announces Preliminary Outcomes of Its Pre-Nda Meeting with the Fda on the Pathway for Approval for Ikt-001Pro in Blood and Gastrointestinal Cancers	Feb. 07	CI
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib	Jan. 29	CI
Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024	Jan. 16	CI
Inhibikase Therapeutics, Inc. Provides Update on Development Programs	Dec. 19	CI
Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro	Dec. 04	CI
Transcript : Inhibikase Therapeutics, Inc., Q3 2023 Earnings Call, Nov 15, 2023	Nov. 15
Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Reports Q3 Revenue $79.6M	Nov. 14	MT
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson?s Disease and Provides Update on Ongoing Enrollment	23-10-16	CI
Sector Update: Health Care Stocks Advancing Late Afternoon	23-10-04	MT
Sector Update: Health Care Stocks Lower Wednesday Afternoon	23-10-04	MT
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Potential Multiple System Atrophy Treatment	23-10-04	MT
Inhibikase Shares Rise Premarket on FDA Orphan Designation for Risvodetinib	23-10-04	DJ
Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib	23-08-24	CI
Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro	23-08-17	CI
Transcript : Inhibikase Therapeutics, Inc., Q2 2023 Earnings Call, Aug 15, 2023	23-08-15
Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts Q2 Revenue $116.4M	23-08-14	MT
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Top Premarket Gainers	23-06-30	MT

Chart Inhibikase Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinsonâs disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinsonâs disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinsonâs-related disorders of the brain and GI tract, orphan indications related to Parkinsonâs disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Companyâs RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.34 USD

Average target price

17.5 USD

Spread / Average Target

+1,205.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INHIBIKASE THERAPEUTICS, INC.	+5.51%	8.68M
MODERNA, INC.	+26.28%	48.09B
IQVIA HOLDINGS INC.	-3.99%	40.43B
LONZA GROUP AG	+45.32%	40.62B
CELLTRION, INC.	-6.20%	28.36B
ICON PUBLIC LIMITED COMPANY	+6.36%	24.89B
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	19.01B
MEDPACE HOLDINGS, INC.	+27.58%	12.09B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.75%	11.8B
BIO-TECHNE CORPORATION	-2.02%	11.88B

Other Biotechnology & Medical Research